Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02914977 · ClinicalTrials.gov registry record · Phase 1
Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia
A Phase 1 study of Acute Myeloid Leukemia and Acute Lymphocytic Leukemia, sponsored by Tara Lin.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT02914977 is a Phase 1 study of Acute Myeloid Leukemia and Acute Lymphocytic Leukemia that has completed, run by Tara Lin. The registered enrollment target is 18 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02914977, a Phase 1 study of Acute Myeloid Leukemia and Acute Lymphocytic Leukemia, has completed, sponsored by Tara Lin.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
In this pilot study, eligible patients will be treated with 5 days of low dose daunorubicin for one cycle only. Any patient who receives treatment on this protocol will be evaluable for toxicity. Each patient will be assessed for the development of toxicity at all scheduled visits (Days 1-5). Following participation on this brief pharmacodynamic trial, patients can then proceed to other conventional or investigational therapies, as clinically indicated.
Conditions Studied
Interventions
- DRUG Daunorubicin
Study Locations (1)
Kansas
- University of Kansas Cancer Center - Clinical Research Center - Fairway
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-11 |
| Est. Completion | 2021-07-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02914977
The ClinicalTrials.gov registry entry for NCT02914977 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (84% lower). The listed sponsor is Tara Lin, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Daunorubicin is the first listed.
NCT02914977 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT02914977 about?
NCT02914977 is a clinical study titled "Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia". In this pilot study, eligible patients will be treated with 5 days of low dose daunorubicin for one cycle only. Any patient who receives treatment on this protocol will be evaluable for toxicity. Each patient will be assessed for the development of toxicity at all scheduled visits (Days 1-5). Follow...
What is the current status of trial NCT02914977?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2016-11. Estimated completion is 2021-07-15.
What conditions does trial NCT02914977 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Acute Lymphocytic Leukemia.
What interventions are being tested in trial NCT02914977?
The interventions under investigation include: Daunorubicin (DRUG).
Who is sponsoring clinical trial NCT02914977?
This trial is sponsored by Tara Lin, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02914977 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 1
-
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
RECRUITING · Phase 1
-
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
RECRUITING · Phase 1
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.